Case Study: Achieving First Patient Enrollment Globally in Multiple Myeloma Clinical Trial

How early patient identification and close sponsor collaboration accelerated site activation and helped turn a patient opportunity into a global-first enrollment

Clinical trial enrollment opportunities don’t always align neatly with site activation timelines. When an appropriate patient is identified before a research site is fully activated, the ability to respond quickly can make the difference between capturing an enrollment opportunity and losing valuable time.

For one multiple myeloma clinical trial, Profound Research identified a potentially eligible patient while final site documentation and sponsor requirements were still being completed.

Rather than wait for the activation process to run its course, the Profound team communicated the opportunity to the sponsor and worked collaboratively to expedite the remaining requirements.

Within four days of identifying the patient, the site achieved Greenlight. The patient was subsequently screened and became the first patient enrolled globally in the trial.

The Challenge: A Patient Opportunity Before Site Activation

On March 7, Profound identified a potential participant for the study—but the site was not yet fully activated.

Sponsor training remained outstanding, the Investigator Site File (ISF) binder was still pending, and final site readiness requirements needed to be completed before the patient could move forward.

The challenge was therefore not simply identifying an appropriate patient. The team needed to complete the remaining activation requirements quickly while maintaining the necessary processes and documentation required to move the study forward.

The Solution: Coordinated Action to Accelerate Site Readiness

Profound promptly communicated the patient opportunity and worked in close coordination with the sponsor to expedite outstanding documentation and site readiness tasks.

The Principal Investigator and site staff completed required Medidata training, the ISF was finalized, and the remaining activation requirements were addressed.

On March 11—just four days after the patient was identified—the site achieved Greenlight.

With activation complete, the team was positioned to move quickly into patient screening and enrollment.

The Outcome: First Patient Enrolled Globally

Following activation, the team continued to move efficiently through the required study activities.

The patient consented on March 17, with the screening visit completed the same day. On March 21 the patient became the first patient enrolled globally in the trial.

Key Study Achievements:

• February 28: Site Initiation Visit (SIV)
• March 7: Patient identified while site activation requirements remained in progress
• March 11: Site activated following completion of sponsor training and ISF requirements
• March 17: Patient consented and screening visit completed
• March 21: First patient enrolled globally

From patient identification before activation to global-first enrollment, the case demonstrates the impact of early patient identification, close sponsor collaboration, and coordinated execution when timing is critical.

What This Means for Sponsors

Early patient identification is valuable only when the operational infrastructure exists to act on the opportunity.

In this multiple myeloma trial, Profound identified a potential participant before the site was fully activated and immediately brought that opportunity forward. Close coordination with the sponsor helped accelerate the outstanding site-readiness requirements while the Principal Investigator and research staff completed the necessary training and documentation.

For sponsors, this kind of proactive communication and operational responsiveness can help reduce avoidable delays between patient identification, site activation, and enrollment.

Looking Ahead

Clinical research rarely follows a perfectly sequential timeline. Patient opportunities can emerge while startup activities are still underway, requiring research teams and sponsors to respond collaboratively and with urgency.

In this multiple myeloma trial, Profound’s early identification of a potential participant, combined with close sponsor coordination, helped the site achieve Greenlight within four days. Ten days later, that patient became the first patient enrolled globally in the study.

The milestone demonstrates what can happen when patient identification, sponsor partnership, and site execution work together toward a shared goal: moving research forward and expanding access to new therapeutic options.